Renaissance Capital logo

Tyra Biosciences Priced, Nasdaq: TYRA

Preclinical biotech developing FGFR kinase inhibitors for solid tumors.

Industry: Health Care

Latest Trade: $15.53 -0.34 (-2.1%)

First Day Return: +62.5%

Return from IPO: -0.8%

Industry: Health Care

We are a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The widespread availability of approved targeted oncology treatments, such as kinase inhibitors, has transformed the cancer treatment landscape. Despite the therapeutic benefit that targeted oncology treatments have created for some patients, the response rate and duration of efficacy is often limited by acquired drug resistance and other shortcomings of existing therapies. We are using our proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. We are initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Our lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. We anticipate filing an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, for TYRA-300 in mid-2022. In addition, we have pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, or RET, and FGFR4-related cancers.
more less
IPO Data
IPO File Date 08/20/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.8
Deal Size ($mm) $173
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/14/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.8
Deal Size ($mm) $173
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Jefferies
more
Company Data
Headquarters Carlsbad, CA, United States
Founded 2018
Employees at IPO 18
Website www.tyra.bio

Tyra Biosciences (TYRA) Performance